Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR -activating mutations (RELAY phase 3 randomized study).

Kazuto Nishio,Kazuko Sakai,Makoto Nishio,Takashi Seto,Carla Visseren-Grul,Michelle Carlsen,Tomoko Matsui,Sotaro Enatsu,Kazuhiko Nakagawa

Translational lung cancer research（2023）

引用 0|浏览18

暂无评分

摘要

ClinicalTrials.gov; identifier: NCT02411448.

查看译文

关键词

Next-generation sequencing (NGS), non-small cell lung cancer (NSCLC), EGFR-activating mutation alleles, circulating tumor-derived DNA, shorter cfDNA fragments

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要